NLS Pharmaceutics AG Announces Sixth Amendment to Merger Agreement with Kadimastem Ltd

Reuters
19 Jul
NLS Pharmaceutics AG Announces Sixth Amendment to Merger Agreement with Kadimastem Ltd

NLS Pharmaceutics AG announced an update regarding its merger and reorganization agreement with Kadimastem Ltd. The Sixth Amendment to the agreement, dated July 18, 2025, involves NLS Pharmaceutics Ltd., Kadimastem Ltd., and NLS Pharmaceuticals (Israel) Ltd. This amendment revises Section 2.1.3(b) of the original agreement, stipulating that NLS Pharmaceutics Ltd. will deliver a certified statement outlining its estimates of closing indebtedness, cash, and adjusted cash amount, along with the resulting merger consideration to be issued. The update highlights the ongoing collaboration and steps toward finalizing the merger process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-065657), on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10